Page 64

Mausner JS, Kramer S. 1985. Epidemiology: An Introductory Text, 2nd edition. Philadelphia: W.B. Saunders Co.

Medical Research Council. 1951. The prevention of whooping cough by vaccination. British Medical Journal 1:1463-1471.

Medical Research Council. 1956. Vaccination against whooping cough: relation between protection in children and results of laboratory tests. British Medical Journal 2:454-462.

Medical Research Council. 1959. Vaccination against whooping cough: the final report. British Medical Journal 1:994-1000.

Melchior JC. 1977. Infantile spasms and early immunization against whooping cough. Danish survey from 1970 to 1975. Archives of Disease in Childhood 52:134-137.

Meyer HM, Parkman PD, Hobbins TE, Larson HE, Davis WJ, Simsarian JP, Hopps HE. 1969. Attenuated rubella viruses: laboratory and clinical characteristics. American Journal of Diseases of Children 118:155-165.

Modlin JF, Brandling-Bennett AD, Witte JJ, Campbell CC, Meyers JD. 1975. A review of five years' experience with rubella vaccine in the United States. Pediatrics 55:20-29.

Perkins FT. 1985. Licensed vaccines. Reviews of Infectious Diseases 7:S73-S76.

Pichichero ME, Badgett JT, Rodgers GC, McLinn S, Trevino-Scatterday B, Nelson JD. 1987. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatric Infectious Disease Journal 6:352-363.

Plotkin SA. 1988. Rubella vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: W.B. Saunders Co.

Plotkin SA, Farquhar JD, Katz M, Buser F. 1969. Attenuation of RA27/3 rubella virus in WI38 human diploid cells. American Journal of Diseases of Children 118: 178-185.

Polk BF, Modlin JF, White JA, DeGirolami PC. 1982. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. American Journal of Epidemiology 115:19-25.

Pollock TM, Miller E, Mortimer JY, Smith G. 1984. Symptoms after primary immunisation with DTP and with DT vaccine. Lancet 2:146-149.

Preblud SR. 1985. Some current issues relating to rubella vaccine. Journal of the American Medical Association 254:253-256.

Prinzie A, Huygelen C, Gold J, Farquhar J, McKee J. 1969. Experimental live attenuated rubella virus vaccine: clinical evaluation of Cendehill strain. American Journal of Diseases of Children 118:172-177.

Ross EM. 1988. Reactions to whole-cell pertussis vaccines. In: Wardlaw AC, Parton R, eds. Pathogenesis and Immunity in Pertussis. New York: John Wiley & Sons.

Rothman KJ. 1986. Modern Epidemiology. Boston: Little, Brown & Co.

Shields WD, Nielsen C, Buch D, Jacobsen V, Christenson P, Zachau-Christiansen B, Cherry JD. 1988. Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. Journal of Pediatrics 113:801-805.

Tingle AJ, Ford DK, Price GE, Kettyls DWG. 1979. Prolonged arthritis in identical twins after rubella immunization (brief report). Annals of Internal Medicine 90:203-204.

Tingle AJ, Chantler JK, Pot KH, Paty DW, Ford DK. 1985. Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia. Journal of Infectious Diseases 152:606-612.

Tingle AJ, Allen M, Petty RE, Kettyls GD, Chantler JK. 1986. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Annals of the Rheumatic Diseases 45:110-114.

Front Matter (R1-R14)

1 Executive Summary (1-8)

2 Histories of Pertussis and Rubella Vaccines (9-31)

3 Methodologic Considerations in Evaluating the Evidence (32-64)

4 Evidence Concerning Pertussis Vaccines and Central Nervous System Disorders, Including Infantile Spasms, Hypsarrhythmia, Aseptic Meningitis, and Encephalopathy (65-124)

5 Evidence Concerning Pertussis Vaccinces and Deaths Classified as Sudden Infant Death Syndrome (SIDS) (125-143)

6 Evidence Concerning Pertussis Vaccines and Other Illnesses and Conditions (144-186)

7 Evidence Concerning Rubella Vaccines and Arthritis, Radiculoneuritis, and Thrombocytopenic Purpura (187-205)

Afterword on Research Needs (206-207)

Bibliography (208-282)

Glossary of Terms (283-292)

Appendix A: Strategies for Gathering Information: Adverse Effects of Pertussis and Rubella Vaccines (293-319)

Appendix B: Pertussis and Rubella Vaccines: A Brief Chronology (320-332)

Appendix C: Animal Models for the Study of Whooping Cough and the Testing of Vaccine Materials (333-336)

Appendix D: Technical Details of Power Calculations and Meta-Analyses (337-346)

Appendix E: Possible Involvement of Aluminum Salts in Erythema Multiforme, Encephalopathy, or Other Adverse Events After Pertussis Immunization (347-348)

Appendix F: Committee and Staff Biographies (349-354)

Index (355-367)